In a groundbreaking move, Max Healthcare has launched CAR-T cell therapy at its Delhi NCR hospital in partnership with ImmunoACT, an IIT Bombay-incubated company. This therapy, known as a 'living drug,' represents a significant leap in the commitment to providing cutting-edge care for cancer patients. The collaboration with ImmunoACT allows for the sourcing of CAR-T cells, with the recent approval from the Central Drugs Standard Control Organisation (CDSCO) for its CAR-T cell therapy product in India.
Revolutionary CAR-T Therapy: CAR-T cell therapy stands as a revolutionary approach in cancer treatment, offering enduring benefits to patients with relapsed/refractory B-cell lymphomas and leukaemia. Dr. Harit K Chaturvedi, Chairman, Max Institute of Cancer Care, emphasized the innovative nature of CAR-T therapy, stating that it reflects Max Healthcare's continuous endeavor to push the boundaries of cancer treatment.
What is CAR-T Therapy: CAR-T therapy, or Chimeric Antigen Receptor T-cell therapy, is an innovative and personalized form of cancer treatment. In this therapy, a patient's own T cells (a type of immune system cell) are collected and genetically modified to express a receptor called a chimeric antigen receptor (CAR) on their surface. The CAR is designed to recognize specific proteins on the surface of cancer cells. Once the T cells are modified, they are multiplied in the laboratory and infused back into the patient. The engineered CAR-T cells can then seek out and attack cancer cells that express the targeted protein. CAR-T therapy has shown remarkable success, especially in treating certain types of blood cancers like B-cell lymphomas and leukaemia. It represents a significant approach to cancer treatment, offering a highly targeted and potent method to combat cancer cells in a patient's body. However, it's worth noting that CAR-T therapy is a complex and specialized treatment, and its application may be limited to certain cancer types and conditions.
Advantages of CAR-T Therapy: Also known as a 'living drug,' CAR-T therapy provides lasting benefits, making it a recommended option for individuals who cannot undergo a stem cell transplant or those experiencing post-transplant relapse. In contrast to traditional therapies, CAR-T therapy requires a brief, single-infusion treatment, significantly improving the quality of life for patients with an average of two weeks of in-patient care.
Significance of the Launch: Dr. Esha Kaul, Director – Haemato-Oncology/Bone Marrow Transplant at Max Super Speciality Hospital, highlighted the importance of this pathbreaking therapy in reinforcing their commitment to delivering personalized and effective solutions. The therapy aligns with the evolving healthcare landscape, contributing to the overall well-being and positive outcomes for patients under their care.
Affordable Access to Life-Saving Treatment: Shirish Arya, Co-founder, and Director – Strategy & Business Development at ImmunoACT, emphasized that the indigenously-developed CAR-T therapy will provide patients in India and countries with limited resources access to this life-saving drug at an affordable cost. This achievement positions the country on the world map of advanced cell-and-gene therapies.
The introduction of CAR-T cell therapy at Max Healthcare, in collaboration with ImmunoACT, signifies a major milestone in the field of cancer treatment in India. This innovative approach not only offers advanced therapeutic options to cancer patients but also addresses the affordability and accessibility challenges associated with life-saving treatments. As healthcare continues to evolve, partnerships like these pave the way for a brighter and more inclusive future in the fight against cancer.